Journey Medical (Journey Medical) Debt-to-EBITDA : -3.19 (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Journey Medical Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Journey Medical's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.10 Mil. Journey Medical's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $14.63 Mil. Journey Medical's annualized EBITDA for the quarter that ended in Dec. 2023 was $-4.62 Mil. Journey Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -3.19.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Journey Medical's Debt-to-EBITDA or its related term are showing as below:

DERM' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.99 Med: 0.58 Max: 7.67
Current: 7.67

During the past 5 years, the highest Debt-to-EBITDA Ratio of Journey Medical was 7.67. The lowest was -0.99. And the median was 0.58.

DERM's Debt-to-EBITDA is ranked worse than
89.02% of 656 companies
in the Drug Manufacturers industry
Industry Median: 1.675 vs DERM: 7.67

Journey Medical Debt-to-EBITDA Historical Data

The historical data trend for Journey Medical's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Journey Medical Debt-to-EBITDA Chart

Journey Medical Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-EBITDA

0.81

0.58

-0.03

-0.99

7.67

Journey Medical Quarterly Data
	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial											-0.66	-0.69	-0.39	-	-3.19

Competitive Comparison of Journey Medical's Debt-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Journey Medical's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Journey Medical's Debt-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Journey Medical's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Journey Medical's Debt-to-EBITDA falls into.

Journey Medical Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Journey Medical's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.099	+	14.631)	/	1.921
	=	7.67

Journey Medical's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(0.099	+	14.631)	/	-4.62
	=	-3.19

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Journey Medical (NAS:DERM) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Journey Medical Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Journey Medical's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Journey Medical (Journey Medical) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Journey Medical Corp (NAS:DERM) » Definitions » Debt-to-EBITDA

Comparable Companies

Traded in Other Exchanges

N/A

Address

9237 E Via de Ventura Boulevard, Suite 105, Scottsdale, AZ, USA, 85258

Website

https://www.journeymedicalcorp.com

Journey Medical Corp is a commercial-stage pharmaceutical company focused on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. The company's portfolio includes eight branded and three authorized generic prescription drugs for dermatological conditions that are marketed in the United States. Some of the group's products are Qbrexza, Accutane, Amzeeq, Exelderm, etc.

Executives

Jeffrey Paley	director	C/O RETROPHIN INC., 777 THIRD AVENUE, 22ND FLOOR, NEW YORK NY 10017
Justin Adam Smith	director	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Rosenwald Lindsay A Md	director	375 PARK AVE, NEW YORK NY 10152
Claude Maraoui	director, officer: President & CEO	C/O JOURNEY MEDICAL CORPORATION, 9237 E VIA DE VENTURA BLVD., SUITE 105, SCOTTSDALE AZ 85258
Joseph Benesch	officer: Interim CFO	C/O TELIGENT, 105 LINCOLN AVENUE, BUENA NJ 08310
De Paolantonio Ernest Robert	officer: Chief Financial Officer	4131 PARKLAKE AVENUE SUITE 225, RALEIGH NC 27612
Neil Herskowitz	director	2109 BROADWAY, SUITE 206, NEW YORK NY 10023
Miranda Jayne Toledano	director	C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135